To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Active· Referred to the House Committee on Energy and Commerce.
Introduced
May 3, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending
Introduced
May 3, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending
Executive Summary
This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.
Action Timeline
3
MAY 03, 2022•IntroReferral
Introduced in House
MAY 03, 2022•IntroReferral
Introduced in House
MAY 03, 2022•IntroReferral
Referred to the House Committee on Energy and Commerce.